Bubnoff, N v. (2018). Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628). BMC cancer. doi:10.1186/s12885-018-5045-7

"Ruxolitinib in GvHD (RIG) study : A multicenter, randomized phase 2 trial to determine the response rate of ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) / Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke and Robert Zeiser" BMC Cancer .

Bubnoff, Nikolas von. "Ruxolitinib in GvHD (RIG) Study: A Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-host Disease (aGvHD) (NCT02396628)." BMC Cancer 2018.